KRT88P and liver disorder: Current guidelines from the American Association for the Study of Liver Diseases (AASLD)state that HBsAg-negative, anti-HBc-positive patients should be started on prophylaxis for HBV when given treatments that target B lymphocytes, such as CAR T-cell therapy.2 HBV prophylaxis should be started either as soon as possible before, or in conjunction with, the onset of immunosuppressive therapy and should be continued for 12 months afterward for patients undergoing anti-CD20 therapies.